MLL1 inhibits the neurogenic potential of SCAPs by interacting with WDR5 and repressing HES1

Mesenchymal stem cell (MSC)-based therapy has emerged as a promising treatment for spinal cord injury (SCI), but improving the neurogenic potential of MSCs remains a challenge. Mixed lineage leukemia 1 (MLL1), an H3K4me3 methyltransferases, plays a critical role in regulating lineage-specific gene e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chen, Ye, Weilong, Zhao, Mengyao, Long, Lujue, Xia, Dengsheng, Fan, Zhipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584904/
https://www.ncbi.nlm.nih.gov/pubmed/37852994
http://dx.doi.org/10.1038/s41368-023-00253-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584904/
https://www.ncbi.nlm.nih.gov/pubmed/37852994
http://dx.doi.org/10.1038/s41368-023-00253-0

Ejemplares similares